Men Are Going to Strike Back
Wait, That's Why Dems Are Scared About ICE Agents Wearing Body Cams
Bill Maher Had the Perfect Response to Billie Eilish's 'Stolen Land' Nonsense
Some Guy Wanted to Test Something at an Anti-ICE Rally. Their Reaction Says...
The Trump Team Quoted the Perfect TV Show to Defend a Proposed WH...
Why This Former CNN Reporter Saying He'd Fire Scott Jennings Is Amusing
Democrats Have Earned All the Bad Things
Don Lemon Plays Civil Rights Martyr After Cities Church Mob Arrest
Canadian PM Carney Just Announced a Plan to Make Canadian Inflation Worse
CA Governor Election 2026: Bianco or Hilton
Same Old, Same Old
The Real Purveyors of Jim Crow
Senior Voters Are Key for a GOP Victory in Midterms
The Deep State’s Inversion Matrix Must Be Seen to Be Defeated
Situational Science and Trans Medicine
Tipsheet
Premium

Surprise, Surprise: Look Where Birx Just Landed a New Job

AP Photo/Alex Brandon

In a bombshell video exposé released by Project Veritas earlier this year, a Pfizer director of research and development spoke openly about the "revolving door" between government and pharmaceutical companies—an arrangement that's "pretty good for the industry but bad for everyone else in America." 

When asked to clarify, he told the undercover PV journalist, "Because if the regulators, who review our drugs, you know that once they stop being a regulator, they want to go work for the company, they are not going to be as harsh on the company where they're getting their job."

One look at where former top officials went after leaving the government confirms this.

Former FDA commissioner Mark McClellan went over to Johnson & Johnson, another former FDA commissioner, Scott Gottlieb, is now at Pfizer, while former FDA commissioner Stephen Hahn is currently in a chief medical officer role at Flagship Pioneering, the investor behind Moderna. And these are just a few examples. 

Most recently, former White House COVID adviser Dr. Deborah Birx, who worked in the federal government for decades, has been added to this "revolving door" list. 

Earlier this month, Birx was appointed CEO of Armata Pharmaceuticals, a California-based biotech company focused on the development of bacteriophage therapeutics that help treat antibiotic-resistant bacterial infections.

"I am thrilled to join Armata at this pivotal time in the Company's development," Birx said in a statement. "I'm impressed with the scientific platform's quality and the team's commitment to introducing innovative treatment options for patients suffering from serious bacterial infections. I am excited about the recent advances and see multiple opportunities to accelerate the Company's progress and drive value creation. The recent investment enables the advancement of AP‐PA02 and AP‐SA02 in Phase 2 clinical trials." 


Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement